# PRAMEF5

## Overview
PRAMEF5 is a gene that encodes the protein PRAME family member 5, which is part of the PRAME (Preferentially Expressed Antigen in Melanoma) gene family. This family is known for its role in various biological processes, including immune response modulation and cell differentiation. The PRAMEF5 protein is categorized as a cancer-testis antigen, which is typically expressed in a restricted manner in normal tissues but is upregulated in certain cancers. This expression pattern makes it a potential target for cancer immunotherapy. Additionally, PRAMEF5 has been implicated in axon guidance pathways, which are essential for proper speech and language development, and has been associated with clinical conditions such as speech and language disorders, as well as certain cancers and muscular dystrophies (Lei2017Axon; Wong2023Validation; Dhivyadharshini2020Decoding).

## Clinical Significance
PRAMEF5, a member of the PRAME gene family, has been implicated in various clinical conditions, particularly in relation to speech and language disorders. Mutations in the PRAME gene family, including PRAMEF5, have been identified in patients with these disorders, suggesting a role in axon guidance pathways that are crucial for speech and language development. Specifically, homozygous missense mutations in the PRAME gene family were found in multiple patients, indicating a potential link to speech/language disorders (Lei2017Axon).

In the context of cancer, PRAMEF5 is part of a group of cancer-testis antigens that are predominantly expressed in tumors and have been associated with poor outcomes in certain cancers, such as head and neck squamous cell carcinoma (HNSCC). The PRAME gene family, including PRAMEF5, is known to modify the retinol pathway, which can contribute to oncogenesis by affecting cell differentiation and immune evasion (Dhivyadharshini2020Decoding). Additionally, PRAMEF5 has been identified as part of a gene signature that can distinguish facioscapulohumeral dystrophy (FSHD) muscle from control muscle, suggesting its potential as a molecular biomarker for this condition (Wong2023Validation).


## References


[1. (Lei2017Axon) Huimeng Lei, Zhangming Yan, Xiaohong Sun, Yue Zhang, Jianhong Wang, Caihong Ma, Qunyuan Xu, Rui Wang, Erich D. Jarvis, and Zhirong Sun. Axon guidance pathways served as common targets for human speech/language evolution and related disorders. Brain and Language, 174:1–8, November 2017. URL: http://dx.doi.org/10.1016/j.bandl.2017.06.007, doi:10.1016/j.bandl.2017.06.007. This article has 15 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.bandl.2017.06.007)

2. (Wong2023Validation) Validation of the association between MRI and gene signatures in facioscapulohumeral dystrophy muscle: implications for clinical trial design. This article has 0 citations.

[3. (Dhivyadharshini2020Decoding) J. Dhivyadharshini, A. S. Smiline Girija, A. Paramasivam, and J. Vijayashree Priyadharsini. Decoding the genetic alterations in prame gene family and its association with head and neck squamous cell carcinoma. Journal of Pharmaceutical Research International, pages 93–102, August 2020. URL: http://dx.doi.org/10.9734/jpri/2020/v32i2030733, doi:10.9734/jpri/2020/v32i2030733. This article has 0 citations.](https://doi.org/10.9734/jpri/2020/v32i2030733)